Industry News

• Ardea Biosciences announces completion of public offering of common stock  Ardea Biosciences announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares sold pursuant to the full exercise of an over-allotment option. Gross proceeds to Ardea from this offering were $166.2 million.
  February 06, 2012  
• Restricting calories early on does not help acute lung injury patients on ventilators  Acute lung injury patients on ventilators who require a feeding tube have a similar number of ventilator-free hospital days and similar mortality rates if they receive a low-calorie feeding program. These results are part of a new clinical study funded by the NHLBI.
  February 06, 2012  
• Genomic Health announces formation of new genetics subsidiary  Genomic Health announced plans to establish a subsidiary with the goal of improving the quality of diagnosis, communication and support for millions of patients and their families faced with common and rare genetic conditions. The subsidiary is expected to be established by March 1, 2012.
  February 06, 2012  
• Acorda Therapeutics nnounces launch of generic version of ZANAFLEX Capsules(R)  Acorda announced that the Company has partnered with Watson Pharma, a subsidiary of Watson Pharmaceuticals, Inc. to introduce tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES® (tizanidine hydrochloride).
  February 06, 2012  
• Synta Pharmaceuticals sells additional 1,050,000 shares of common stock  Synta announced completion of the sale of 1,050,000 additional shares of common stock pursuant to the full exercise of the over-allotment option granted to the underwriters of its previously announced public offering. After underwriting expenses, net proceeds from the offering were $32.9 million.
  February 06, 2012  
• Valeant Pharmaceuticals completes divestiture of generic dermatology products to Mylan  valeant announced it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, an authorized generic of Efudex, to Mylan Inc.
  February 06, 2012  
• Neuralstem to raise $5.2 million in registered direct offering  Neuralstem announced that it has entered into agreements with certain institutional and accredited investors for a registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share for aggregate gross proceeds of $5,200,000.
  February 06, 2012  
• Fending off cardiovascular disease  A study of data from over a quarter of a million people confirmed that traditional risk factors for cardiovascular disease, such as high blood pressure, substantially raise the chance of major CVD events like heart attack or stroke over the course of a lifetime.
  February 06, 2012  
• CYTX awarded patents to treat wounds with stem cells  Cytori has been issued US Patent No. 8,105,580 covering methods of using adipose-derived stem and regenerative cells extracted by self-contained adipose tissue processing devices such as our Celution® System, to heal wounds, including non-healing diabetic wounds.
  February 06, 2012  
• Boston Scientific announces global launch of Expect™ 19 Flex endoscopic  Boston Scientific announced the global launch of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples under Endoscopic Ultrasound guidance for cancer diagnosis in organs adjacent to the gastrointestinal tract.
  February 06, 2012  

   (next 10 articles)